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Abstract: 
 
Repetin (RPTN) protein is a member of S100 family and is known to be expressed in the normal 
epidermis. Here we show that RPTN is ubiquitously expressed in both mouse and human brain, 
with relatively high levels in choroid plexus, hippocampus and prefrontal cortex. To investigate 
the expression of RPTN in neuropsychiatric disorders, we determined serum levels of RPTN in 
patients with schizophrenia (n = 88) or bipolar disorder (n = 34) and in chronic psychostimulant 
users (n = 91). We also studied its expression in a mouse model of chronic unpredictable mild 
stress (CUMS). The results showed that serum RPTN levels were significantly diminished in 
patients with schizophrenia and bipolar disorder or in psychostimulant users, compared with 
healthy subjects (n = 115) or age-matched controls (n = 92) (p < 0.0001). In CUMS mice, RPTN 
expression in hippocampus and prefrontal cortex was reduced with progression of the CUMS 
procedure; the serum RPTN level remained unchanged. Since CUMS is a model for depression 
and methamphetamine (METH) abuse induced psychosis recapitulates many of the psychotic 
symptoms of schizophrenia, the results from this study may imply that RPTN plays a potential 
role in emotional and cognitive processing; its decrease in serum may indicate its involvement in 
the pathogenesis of schizophrenia and bipolar disorder. 
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Repetin (RPTN) protein is a member of S100 family and is known to be expressed in the normal epidermis.
Here we show that RPTN is ubiquitously expressed in both mouse and human brain, with relatively high
levels in choroid plexus, hippocampus and prefrontal cortex. To investigate the expression of RPTN in
neuropsychiatric disorders, we determined serum levels of RPTN in patients with schizophrenia (n 5 88) or
bipolar disorder (n 5 34) and in chronic psychostimulant users (n 5 91). We also studied its expression in a
mouse model of chronic unpredictable mild stress (CUMS). The results showed that serum RPTN levels
were significantly diminished in patients with schizophrenia and bipolar disorder or in psychostimulant
users, compared with healthy subjects (n 5 115) or age-matched controls (n 5 92) (p , 0.0001). In CUMS
mice, RPTN expression in hippocampus and prefrontal cortex was reduced with progression of the CUMS
procedure; the serum RPTN level remained unchanged. Since CUMS is a model for depression and
methamphetamine (METH) abuse induced psychosis recapitulates many of the psychotic symptoms of
schizophrenia, the results from this study may imply that RPTN plays a potential role in emotional and
cognitive processing; its decrease in serum may indicate its involvement in the pathogenesis of
schizophrenia and bipolar disorder.
S
chizophrenia and bipolar disorder are considered to be ‘‘multiple hit’’ diseases, stemming from genetic and
environmental influences1,2. Although the etiology of these diseases is largely unknown, there is growing
evidence that dysregulation of calcium signaling is involved3,4. Calcium-binding proteins are mediators of a
variety of cellular processes including calcium signaling. Parvalbumin (PV) is a calcium binding protein that is
frequently reduced in PV basket cells in the prefrontal cortex and hippocampus of schizophrenic subjects5,6.
Decreased densities of PV-positive interneurons in the para- and hippocampal regions was also observed in both
bipolar disorder and schizophrenia7,8, indicating hippocampal dysfunction in those disorders and a potential key
role for PV in the pathophysiology of schizophrenia6. Calcium binding protein S100B is abundant in CNS and has
been suggested to be a susceptibility gene for bipolar disorder, schizophrenia and cognitive dysfunction9. In
bipolar patients, the densities of S100B-immunopositive astrocytes in the CA1 pyramidal layer and S100B-
immunopositive oligodendrocytes in the left alveus are decreased10. In schizophrenia, S100B is increased in
the cerebrospinal fluid (CSF), indicating glial cell dysfunction11. Whether an elevated serum level of S100B is a
marker for psychotic illness still remains controversial. Some studies have suggested that S100B is an indicator of
astrocyte activation and brain dysfunction12–14; in contrast, others have claimed that it is neither an intermediate
phenotype nor a trait marker15.
The human repetin (RPTN) protein is a new member of the S100 family with two EF-hand domains in the N-
terminal that can reversely bind calcium. RPTN was originally identified as a member of the "fused" gene family
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that is associated with keratin intermediate filaments16. RPTN
expression was found in normal epidermis but is also high in the
acrosyringium, the inner hair root sheath and in the filiform papilli of
the tongue17.
Until recently, RPTN was not known to have any function in the
nervous system, or even to be expressed in the brain. In this study, we
examined its expression in the CNS and in sera from patients with
schizophrenia and bipolar disorder, and from psychostimulant users.
We also employed the chronic unpredictable mild stress (CUMS)18
mouse model to investigate whether RPTN is potentially involved in
the development of emotional and cognitive dysfunctions.
Methods
Atypical antipsychotics. Olanzapine was obtained from Jiangsu Hansoh
pharmaceutical Co. and dissolved in 0.1 M HCl, pH-adjusted to 5.5 using 0.1 M
NaOH and diluted with PBS to a final concentration of 0.025 mg/ml. Quetiapine
fumarate was purchased from Hunan Dongting pharmaceutical Co., ltd. and
dissolved in PBS at a final concentration of 0.75 mg/ml. Aripiprazole was purchased
from Shanghai Zhongxi pharmaceutics and dissolved in PBS containing 5% DMSO.
Antibodies and western blot kit. Rabbit anti-human RPTN polyclonal antibody (cat.
LS-B17) was purchased from LifeSpan BioSciences, Inc., USA. The antibody reacts
with both human and mouse RPTN. Anti-b-actin (CB10099M) was purchased from
California bioscience, USA; Goat anti-Rabbit IgG-HRP was purchased from Santa
Cruz Biotech (cat. SC-2004). The SuperSignal West Pico kit (cat. 34079) was
purchased from Thermo Scientific, USA.
Normal human brain chip. A normal human brain chip was purchased from US
Biomax, Inc (cat. BNC17011). The chip is a normal brain tissue microarray of 26
cases/80 cores, containing three cases each of frontal lobe,apical lobe, occipital
lobe,temporal lobe, midbrain, pons,medulla oblongata, thalamus opticus, cerebellum,
hippocampus, callositas, optic nerve and spinal cord tissue, plus one case of caudate
nucleus, with duplicate cores in each block.
Animals. Mouse CUMS model. The animal protocol of this study was approved by
national legislations of China and local guidelines. The investigation was conducted
in accordance with the ethical principles of animal use and care. 27 six-week old male
BALB/c mice of 20–24 g weight were obtained from the animal center of Xi’an
Jiaotong University and divided into two groups. Unless otherwise specified, mice
were housed under a 12-hour light/12-hour dark cycle with free access to water and
standard mouse diet (66% carbohydrate, 12% fat, 22% protein). 11 mice were
maintained as control group, 16 mice were housed in individual cages and assigned as
CUMS group. The CUMS mouse model was developed following the reported
procedure18. Briefly, nine types of mild stressors (cage tilting, light–dark cycle,
swimming in 4uC cold water, swimming in 45uC warm water, water deprivation, food
deprivation, tail nip, shaking, and damp sawdust) were arranged randomly over a 21-
day period and employed to stress mice. Mice were exposed to the stressors
individually. Stressors were never performed simultaneously. Mice in the control
group were not subjected to any stressors. The CUMS procedure used in this study
has been employed successfully in our lab in both rats and mice19. Because the tail
suspension test (TST) is widely recognized as a useful experimental paradigm for
assessing depression-like behavior20,21, TST was performed after 21 days of CUMS
procedure to validate the model. Briefly, each mouse was suspended individually by
its tail using adhesive laboratory tape to a flat metal bar connected to a strain gauge
within a tail suspension chamber, Tail Suspension Monitor (TSE, German). The
duration of the test was 6 min. Data acquisition and analysis was performed
automatically. After collecting the blood samples, the brains from control and CUMS
mice were first perfused with 4% paraformaldehyde in PBS and then embedded in
paraffin. Five-mm sagittal sections of mouse brain were prepared for
immunohistochemical examination.
Immunohistochemitry. To investigate the expression pattern of RPTN in brain,
mouse brain and human brain chips were treated with Rabbit anti-RPTN antibody
(LS-B17). Briefly, after dewaxing and rehydration, sections were blocked with 20%
blocking serum in TBS/0.1% Tween. Sections were then incubated with Rabbit anti-
RPTN primary antibody (2.5 mg/ml) overnight at 4uC. The bound primary antibodies
were detected using an EnVision 1 Dual Link System-HRP (K4063, Dako, USA).
Slides were counterstained with hematoxylin.
Western blotting for RPTN alteration in CUMS mouse brain. To investigate
alterations in RPTN expression during the CUMS procedure, 16 six-week old male
BALB/c mice of 20–24 g weight were used in CUMS modeling as described above.
Hippocampus and prefrontal lobes from four mice were removed on days 0,7,14 and
21. The tissue homogenates were freshly prepared by sonication in lysis buffer
(50 mM Tris-HCL, 2 mM EDTA, 2 mM PMSF, pH 7.4) in an ice bath. Following
homogenization, the tissue preparation was centrifuged for 2 minutes at 13,000 3 g to
collect the supernatant. The supernatants from each time point were stored at 280uC
and used to run Western blots at the end of the CUMS procedure. Briefly, 40 mg of
total protein from each mouse preparation of hippocampus or prefrontal cortex was
applied on 10% SDS-PAGE gels for electrophoresis. After transferring onto PVDF
membrane, the membrane was blotted with Rabbit anti-mouse RPTN antibody
overnight at 4uC. After washing three times with PBS containing 0.05% of Tween-20,
the membranes were incubated with goat anti Rabbit IgG-HRP for one hour at room
temperature. Finally, SuperSignal West Pico substrate was applied and images were
obtained by x-ray film exposure. b-actin was used as an endogenous control. The
blotting procedure was repeated on four mice from days 0,7,14 and 21. Densitometry
analysis was used to measure the level of RPTN relative to b-actin in each sample and
expressed as arbitrary units (a.u). The alteration of RPTN in hippocampus or
prefrontal lobe was statistically analyzed, with day zero animals used as a normal
control.
Serum samples from human subjects. Healthy control sera (n 5 115) were obtained
from the physical examination center at the School of Medicine Xi’an Jiaotong
University, Xi’an, China. Sera from patients with schizophrenia (n 5 88) or bipolar
disorder (n 5 34) and from drug users (n 5 91) were collected from Xi’an mental
health center, Xi’an, China. Patients with schizophrenia or bipolar disorder were
diagnosed by two psychiatrists according to ICD-10 criteria. All patients were
inpatients under antipsychotic therapy at the time that blood samples were collected.
The great majority of the patients were receiving atypical antipsychotics and mood
stabilizers. Olanzapine, Quetiapine and Aripiprazole were mostly used by the
patients. Drug users were enrolled from the methadone maintenance treatment
program of Xi’an mental health center. All drug users had at least a three-year history
of poly-drug (methamphetamine (METH) and heroin) abuse. There was no
significant difference between healthy controls and patients in sex or age distribution,
but drug users were predominantly males (Table 1).
Serum samples from CUMS mice and Mice treated with atypical antipsychotics. 36
six-week old male BALB/c mice of 20–24 g weight were obtained from the Animal
Center of Xi’an Jiaotong University. Animals were divided into four groups and
administered intraperitoneally with atypical antipsychotics Olanzapine (n 5 9),
Quetiapine (n 5 7), Aripiprazole (n 5 9) or PBS as control (n 5 11) for 24 days. The
dosages for Olanzapine, Quetiapine and Aripiprazole were 0.5 mg/kg/day22, 15 mg/
kg/day23 and 5 mg/kg/day24, respectively. Sera were collected on day 25 for ELISA
assays.
ELISA assay. Human and mouse RPTN ELISA kits (cat. CSB-EL020501HU, CSB-
EL02051MO) were purchased from CUSABIO, Inc., Wuhan, China, with 156 and
Table 1 | Demographics of serum samples from healthy controls and patients
Control Schizophrenia Bipolar Disorder Drug user
Gender 58 M, 57 F 44 M, 44 F M 18, 16 F 84 M, 7 F
Age 40.77 6 13.26 38.87 6 15.33 36.65 6 15.07 47.5 6 6.62
Duration of illness (years) - 11.30 6 10.1 10.06 6 6.39 .3
Methadone-maintained - - - 91
SANS - 31.37 6 22.99# n.a -
SAPS - 21.09 6 12.50# n.a -
Adjunct therapies (Bio-electric etc) - 69 30 -
Typical Antipsychotics - 3 1 -
Atypical - 85 33 -
Antipsychotics
Antipsychotics plus - 40 34 -
mood stabilizer
M: male; F: female; n.a.: not available or a few were recorded; #: the latest scores.
www.nature.com/scientificreports
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78 pg/ml of the minimum detectable dose of RPTN, respectively. RPTN
concentrations in collected serum samples from human subjects and mice were
determined according to the manufacturer’s instructions.
Statistical analysis. Kruskal-Wallis test was run in comparisons among multiple
groups of humans or animals being compared. A two-tailed unpaired Mann-Whitney
test was used in comparing two-group studies. One-way ANOVA followed by post-
hoc Dunnett’s test was run in comparisons among RPTN Western Blots.
Results
Expression of RPTN in human and mouse brain. RPTN was found
to be ubiquitously expressed in human brain, with relatively high
levels in choroid plexus (ependymal cells), hippocampus and
prefrontal lobe (Figure 1,a,b,c) and weak staining in the temporal
lobe (Figure 1,d). In normal mouse brain, strong RPTN-
immunopositive staining is seen in locus ceruleus (LC), choroid
plexus (ependyma), hippocampal CA3 and CA2 pyramidal layer
and prefrontal cortex (Figure 2-a,b,c). Subcellularly, RPTN is
expressed as puncta in the cytoplasm (Figure 1, b,c, inserts).
Decreased expression of RPTN in hippocampus and prefrontal
lobe of CUMS mice. The TST test showed CUMS mice had
significantly longer periods of immobility compared to normal
animals (284.4 6 2.14 sec/6 min vs. 241.9 6 9.05 sec/6 min, p ,
0.001). Since hippocampus and prefrontal lobe are two regions that
are significantly affected in emotional and cognitive disorders25, we
studied alterations in RPTN expression in these regions in mice
subjected to the CUMS procedure, a widely used animal model for
the study of major depression18. Over the 21-day period of CUMS
procedure, RPTN protein levels in hippocampus and prefrontal
cortex gradually declined, as determined by Western blot
(Figure 2-d).
Serum RPTN levels in normal human subjects, schizophrenia, and
bipolar disorder. Given that the detection limit for the human
RPTN kit is 156 pg/ml, all serum samples with RPTN level below
156 pg/ml were assigned as RPTN undetectable. Then, the median of
each group was used to indicate the average level of serum RPTN.
Kruskal-Wallis test was used to analyze the data (Table 2). In normal
human subjects, the median serum RPTN is 915.0 pg/ml (n 5 115),
but some samples had levels as high as 10,000 pg/ml serum RPTN.
Of 88 schizophrenia serum samples, the median RPTN
concentration is 156.0 pg/ml; of these only two samples showed
detectable levels of 163 pg/ml and 309 pg/ml, whereas most
patient sera (97.7%) showed an undetectable level of RPTN. In 34
bipolar disorder patients, serum RPTN had a median of 156.0 pg/ml;
three samples had 165, 303 and 308 pg/ml RPTN; all the rest of the
samples (91.2%) were RPTN undetectable with the current ELISA
method. The difference of serum RPTN levels between healthy
controls and the patients was extremely significant (p , 0.0001)
(Figure 3-a). Since almost all patients had nearly undetectable
levels of RPTN, medication use or duration of illness were thus
unlikely to be correlative factors to RPTN levels. There was no
significant difference in serum RPTN levels between schizophrenia
and bipolar disorder. In normal human subjects, serum RPTN levels
among the age groups or between male and female were not
significantly different (Figure 3-b, c).
Figure 1 | Immunohistochemical detection of RPTN expression in normal human brain. a, choroid plexus (ependyma). b, hippocampus. c, prefrontal
lobe. d, temporal lobe. The inserts are high-power images of selected regions. Scale bars are 50 mm. Scale bars in the inserts are 10 mm.
www.nature.com/scientificreports
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Serum RPTN levels in drug users and age-matched normal human
subjects. The median serum RPTN of drug users (n 5 91) was
156.0 pg/ml (156.0 at 25% percentile and 738.0 at 75% percentile),
compared to 1034 pg/ml (352.8 at 25% percentile and 2518 at 75%
percentile) in age-matched normal subjects (n 5 92). The drug users
showed a significant reduction of serum RPTN compared to age-
Figure 2 | Immunohistochemistry and Western blot detection of RPTN expression in mouse brain. a, Choroid plexus (fourth ventricle), ependyma and
locus coeruleus. b, hippocampus. c, prefrontal cortex. d, lower panels are Western Blot of RPTN and endogenous b-actin control in the
hippocampus and prefrontal cortex of mice subjected to CUMS on day 0 to 21; upper graph is the densitometry analyses of RPTN over corresponding b-
actin and expressed as arbitrary units (au) (n 5 4). Scale bars are 50 mm. ** p , 0.05, *** p , 0.0001.
Table 2 | Statistical analyses (Kruskal-Wallis multiple comparison test)
Serum RPTN (pg/ml) Sample size Median 25% percentile 75% percentile P Value#
Human
Healthy controls 115 915.0 364.0 2003.0
Schizophrenia 88 156.0 156.0 156.0 ,0.0001
Bipolar disorder 34 156.0 156.0 156.0 ,0.0001
Age-matched controls 92 1034.0 352.8 2518.0
Methamphetamine users 91 156.0 156.0 738.0 ,0.0001##
Animals
Normal mice 11 340.0 240.0 608.0
CUMS mice 16 494.0 318.5 648.8 ns
Olanzapine treatment 9 924.0 770.0 1236.0 ,0.0001
Quetiapine treatment 7 800.0 770.0 1080.0 ,0.05
Aripiprazole treatment 9 609.0 379.5 905.5 ns
#: compared with controls of human or mice; ##: compared with age-matched controls; ns: no significance.
www.nature.com/scientificreports
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matched healthy human subjects (p , 0.0001), but a significant
elevation of RPTN relative to the schizophrenia group (p ,
0.0001) (Table 2 and Figure 4-a).
Serum RPTN levels in normal mice, CUMS model mice and drug
treated mice. Since the majority of the patients enrolled in the study
were under atypical antipsychotic therapy, to rule out the possibility
that the reduction of serum RPTN was due to antipsychotics, we tested
the effect of three widely used drugs on serum RPTN levels in mice.
Normal mice had a median serum RPTN of 340.0 pg/ml; as compared
to 924.0, 800.0 or 609.0 pg/ml in mice treated with Olanzapine,
Quetiapine or Aripiprazole, respectively. Statistical analysis indicated
no effect on serum RPTN level from Aripiprazole treatment, but there
was a significant increase in serum RPTN from Olanzapine or
Quetiapine treatment. However, the results did not show a
significant difference between CUMS (494.0 pg/ml) mice and
normal mice in serum RPTN levels.
To confirm the reliability of the ELISA kit used in the study, a
recovery experiment was performed with both low (300 pg/ml) and
high (2500 pg/ml) RPTN concentrations. The recovery rates of low
and high concentrations of RPTN were 104 6 16.9% and 102 6
13.5%, respectively (n 5 8).
Discussion
RPTN was previously only known to be expressed in normal epi-
dermis; this study is the first time that RPTN expression in brain has
been reported.
Our primary finding is that serum RPTN is significantly dimin-
ished in patients with schizophrenia and bipolar disorder. The results
obtained in mice treated with antipsychotics for 24 days may not rule
out completely the possibility that the reduction of serum RPTN in
the patients is the result of multi-year antipsychotic therapy, but this
confounding possibility would not be applicable for comparison to
patients under acute antipsychotic medication. In contrast, atypical
antipsychotics actually increase the serum level of RPTN in mice.
Similarly, S100B is increased in schizophrenics who are being treated
with antipsychotics26. Since almost all patients had nearly undetect-
able levels of RPTN, no correlation between disease severity and
RPTN concentration in serum is suggested, which is also quite sim-
ilar to the reported role of S100B in schizophrenia13,14. It is note-
worthy that a few normal subjects also had undetectable RPTN
levels. The low levels of RPTN in the normal subjects may be due
to the limited sensitivity of the detection kit used in this study. A
more sensitive detection method may differentiate the healthy sub-
jects with low RPTN levels from the psychiatric patients. Meanwhile,
we cannot rule out the possibility that those normal subjects with
undetectable serum RPTN may be inflicted with minor covert emo-
tional or cognitive disorders. From the results of the CUMS mouse
model in this study, stress had such a significant effect on RPTN
expression that a significant decrease appeared in as little as one
week, in both hippocampus and prefrontal cortex (Figure 2-d).
Due to the lack of postmortem samples, this study was only able to
analyze RPTN levels on a normal human brain chip. We have not
found out any relevant information about RPTN alterations in avail-
able microarray data such as a transcriptome of postmortem brains
of schizophrenics27, proteomic analyses of schizophrenia hippocam-
pus28 and gene expression profiles of dorsolateral prefrontal cortex of
schizophrenia patients29. Changes in S100B have been frequently
identified in schizophrenia, but it is not found in these databases
either. Although the reduction of RPTN in CUMS mouse brain
may not suggest a role in the reduction of serum RPTN in schizo-
phrenia, there is evidence that depression and schizophrenia often
affect the same brain regions30–33. To confirm further the alteration of
serum RPTN in patients with schizophrenia, we analyzed the serum
RPTN levels in poly-drug users. A nation-wide survey of drug abuse
in China showed most heroin users have used METH frequently34.
The 91 poly-drug users in this study have used both heroin and
METH for more than 3 years. The prevalence of comorbid psychi-
atric disorders among drug users under methadone maintenance
treatment is almost six times higher than that of normal subjects35.
Chronic heroin use could reduce serum neurotrophins such as brain-
derived neurotrophic factor (BDNF) and thus may increase the risk
of developing psychosis36, while chronic METH abuse induced
psychosis recapitulates many of the psychotic symptoms of schizo-
phrenia37. The reduction of serum RPTN in poly-drug users may
thus reflect its decrease in schizophrenia. RPTN expression is
Figure 3 | Serum RPTN levels in control and patients with schizophrenia (SCZ) or bipolar disorder (BP). a, serum RPTN levels in control (C), SCZ and
BP. b, serum RPTN levels in different age groups of control, from 30 years and under to 71–80 year group. c, serum RPTN in males and females
of control. ***p , 0.0001.
www.nature.com/scientificreports
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reduced in hippocampi and prefrontal lobes of CUMS mice, but the
serum RPTN level remains unchanged. The different patterns of
expression of RPTN between CUMS mice and schizophrenic
patients may imply its universal role in the pathogenesis of neurop-
sychiatric disorders. Whether the alteration of RPTN is a contributor
to, or is a consequence of the diseases remains to be elucidated. A
future study on postmortem brain or in vivo examination via imaging
techniques may help elucidate the mechanisms involved.
The origin of serum RPTN is currently unclear. In this study,
serum RPTN levels are increased in mice treated with atypical anti-
psychotics, but decreased in poly-drug users. Given that METH can
stimulate the release of serotonin (5HT), dopamine (DA) and nor-
epinephrine (NE)38 while atypical antipsychotics act as antagonists of
5HT/D2, this may imply that serum RPTN is regulated by the DA
neurotransmitter system.
RPTN functions in the cornified cell envelope formation17, but its
role in the CNS remains unknown. RPTN protein contains two EF-
hands, which structurally resemble the calcium binding domain of
PV17. Calcium-binding proteins play important roles in the brain and
in psychiatric disorders. PV is regarded as a neuronal marker and has
a potential key role in the pathophysiology of schizophrenia39, as its
reduction in ventral hippocampus can induce an augmented DA
system function and behavioral hyper-responsivity to amphet-
amine6. The calcium-binding proteins calbindin (CB), calretinin
(CR) and PV are considered as markers of specific subpopulations
of cortical GABAergic interneurons. The densities of CB-immunor-
eactive neurons in layer 2 and PV-immunoreactive neurons in layer 4
in schizophrenia subjects are decreased40. S100B is another calcium-
binding protein that is increased significantly in the sera of schizo-
phrenic patients41; its elevation in the CSF may indicate dysfunction
of glial cells and the blood-brain barrier in schizophrenia11,42.
The hippocampus and prefrontal cortex are strongly implicated in
depression, bipolar disorder and schizophrenia1,5,43–45. Postmortem and
brain imaging studies of depressed and anxious patients show that
chronic stress can affect prefrontal cortex and hippocampus30,31.
Presynaptic abnormalities and prefrontal cortical dysfunction were
reported to exist in schizophrenia46. Deficits in functional integration
between prefrontal cortex and hippocampus, or their dysfunctions, have
been associated with cognitive impairment in schizophrenia32,33. RNA-
Seq data from the hippocampus has indicated that abnormal immune/
inflammation response in the hippocampus may underlie the patho-
physiology of schizophrenia and may be associated with abnormalities
in the PV-containing neurons that lead to the cognitive deficits of the
disease47. In the hippocampus, the CA1 pyramidal layer shows bilat-
erally decreased S100B-immunopositive astrocytes in major depressive
disorder and bipolar disorder patients10. CA2 and CA3 regions were
affected to a significantly greater degree than other hippocampal regions
in patients with schizophrenia and bipolar disorder28. In this study, the
relatively high levels of RPTN in CA3 and CA2 regions of the hip-
pocampus and prefrontal lobe (figure 1,b-c; figure 2,b-c) may suggest a
role of RPTN in the process of emotional and cognitive regulation.
Accordingly, the reduced expression of RPTN in hippocampus and
prefrontal cortex of the CUMS mouse (figure 2-d) may further imply
its involvement in depression, schizophrenia and bipolar disorder.
Figure 4 | Serum RPTN levels in human subjects of drug users, age-matched healthy controls and schizophrenia (SCZ) and in normal and CUMS mice
and mice treated with atypical antipsychotics. a, serum RPTN levels in drug users and age-matched healthy controls and schizophrenic patients.
b, serum RPTN levels in normal and CUMS mice and mice treated with Olanzapine, Quetiapine or Aripiprazole for 24 days. *p , 0.05, ***p , 0.0001.
www.nature.com/scientificreports
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In this study, RPTN showed high expression levels in the choroid
plexus and ependyma (figure 1-a, figure 2-a). A previous study found
that an epidermal calcium-binding protein was detected in the epen-
dyma of brain48. Schizophrenia may result from covert immune
complex disease of the basal lamina of the choroid plexus, which is
similar to the structures of skin49. The presence of choroid plexus
calcification (CPC) is associated with hippocampal, frontal, tempor-
oparietal and cerebellar atrophies. CPC may be a predictive indicator
of poor evolution or of a neurodegenerative type50, a neuroradiolo-
gical marker of hallucinations51 or depression in schizophrenia52.
There is also a possible correlation between CPC and dysgenetic or
functional 5HT alteration53. RPTN is a component of the skin bar-
rier54,55, so its presence in choroid plexus and ependymal cells may
suggest its role in maintaining the integrity of blood-CSF barrier and
associated functions.
Interestingly, RPTN showed the highest expression level in the LC
in mouse brain (figure 2-a). In the human brain chip, however, LC
was not identified, because the chip contained no LC region. LC has
been proposed to be involved in the pathophysiology of aging and
schizophrenia, since its volume is reduced in schizophrenic brains56,
but DA-beta-hydroxylase activity was increased in the rostral part57.
A neuromelanin-sensitive magnetic resonance imaging study found
that the contrast ratio of LC to the adjacent white matter in depress-
ive patients was significantly lower than that of control subjects and
schizophrenic patients58. The LC is the principal site for brain syn-
thesis of NE. Catecholamine neurons are considered as the main
target of METH since METH is a powerful DA and NE releaser59.
Therefore, serum RPTN reduction in drug users may imply its
involvement in the LC-noradrenergic system.
Collectively, being a calcium-binding protein expressed in crucial
regions in brain, RPTN may have roles in calcium homeostasis or/
and calcium signaling. Since dysregulation of the calcium-signaling
pathway has been implicated in the development of bipolar disorder
and schizophrenia3,4, the diminished serum RPTN observed in the
patients suggests its possible involvement in the pathogenesis of
those disorders.
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